ClinicalTrials.gg
RecruitingNCT06782815Updated Feb 11, 2025

Acupoint Selection Based on Meridian Theory in Primary Insomnia of Liver Depression and Spleen Deficiency Type

An interventional study of Acupuncture and Acupuncture in Primary Insomnia, sponsored by Chuanlong Zhou. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Chuanlong Zhou · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2024, registered Dec 2024).
  • Started Jan 2024; still recruiting 2 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The classical literature combined with modern medicine to select acupoints, in order to intervene in the autonomic nerve function of the superior cervical sympathetic ganglion as an opportunity, put forward the meridian acupoints mainly to reconcile the head orifices Ying Wei, acupuncture treatment of primary insomnia clinical research. Heart rate variability ( HRV ), Pittsburgh sleep quality index ( PSQI ), polysomnography ( PSG ) and the MOS item short from health survey ( SF-36 ) were observed. Insomnia Severity Index ( ISI ), Dysfunctional Beliefs and Attitudes about Sleep Scale 16 ( DBAS-16 ), GABA, Glx and other secondary indicators were used to clarify the clinical short-term and long-term efficacy of different acupoints in the treatment of patients with primary insomnia and the intervention effect on HRV.

Read the detailed description

In this randomized controlled trial, 96 patients with insomnia of liver depression and spleen deficiency type were selected from the Third Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine. All patients will be randomly assigned to the control group or the acupuncture group.

MAIN OUTCOME MEASURES : Pittsburgh Sleep Quality Index ( PSQI ) was used to measure sleep quality, and 36-Item Short Form Health Survey ( SF-36 ) was used to measure quality of life. Secondary outcomes included the Insomnia Severity Index ( ISI ), Sleep Dysfunction Beliefs and Attitudes Scale 16, DBAS-16, GABA and Glx.

02

Conditions studied

  • Primary Insomnia

Keywords

  • Liver stagnation and spleen deficiency type insomnia
  • Acupuncture
  • Randomized controlled trial
03

In context

Sleep Initiation and Maintenance Disorders

1,925 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 612 are open to participants now.

This study's planned enrollment of 96 is above the median of 72 across 1,689 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

This is the only study on the registry with Chuanlong Zhou as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In line with the diagnostic criteria of insomnia of liver depression and spleen deficiency type in traditional Chinese medicine :
  • In line with the Western diagnostic criteria for insomnia ;
  • 18 ≤ age ≤ 40 years old, male or female ;
  • patients with a course of more than two weeks ; Note: The above criteria must be met for inclusion in this study.

Exclusion criteria

Exclusion Criteria:

  • Insomnia caused by a variety of organic diseases, neurological or psychiatric disorders
  • Pregnancy, lactation or drug allergy
  • There are more serious primary diseases such as cardiovascular and cerebrovascular diseases, gastrointestinal diseases, endocrine system diseases, or psychiatric patients.
  • Patients with coagulation dysfunction and bleeding tendency.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Sham comparator
    Control group

    This group will include 48 patients. Conventional acupuncture, patients take the supine position

    Device: Acupuncture

  • Experimental
    Acupuncture group

    This group will include 48 patients. The patient was placed in a supine position.

    Device: Acupuncture

Interventions

  • DeviceAcupuncture

    acupuncture Baihui, Sishencong ; acupuncture bilateral Qimen, Zhangmen, Hegu, Taichong, reinforcing and reducing, until the acid swelling is obvious,stopped ferforming acupuncture, the needle was retained for 30 min.

  • DeviceAcupuncture

    (1)Acupuncture bilateral Tianrong points, obliquely 45 ± 5 ° backward, 1-1.5 inch deep, reinforcing and reducing horizontally, and stop the needle when the auricle has a heat sensation ; (2)Acupuncture at bilateral Tianyou points, pointing to the tip of the nose, with a depth of 0.5-1 inches, flat reinforcing and reducing, until the sense of soreness and distension obviously stops, and the needle is retained for 30 minutes.

06

What researchers measure

Primary outcomes

  1. Sleep quality measured by Pittsburgh sleep quality index ( PSQI)

    The patients will be assessed by PSQI Chinese fixed questionnaire at each observation point and the clinical efficacy will be observed.It consists of 19 self-evaluation and 5 other-evaluation items. Only 19 self-evaluation questions are scored, and 19 self-evaluation questions are composed of 7 factors, each factor consists of 7 factors of 0-3 points. '0 ' refers to no difficulty, ' 3 ' refers to very difficult. The total score of ' 21 ' refers to very difficult in all respects. The sum of all factor scores constitutes the total score of the 0-21 scale. The reference boundary value of adult sleep quality problems in China : poor sleep quality : PSQI ≥ 8 ; good sleep quality : PSQI ≤ 7 ; the higher the score, the worse the sleep quality.

    Time frame: Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.

  2. Quality of life measure by 36-item short form health survey(SF-36)

    The patients will be evaluated by SF-36 scale at each observation point. The SF-36 scale is a general scale developed by the American Medical Research Group to evaluate the quality of life. It is widely recognized and widely used in the world. This scale has eight dimensions to evaluate health-related quality of life ( HRQOL ), which belong to two categories of physical health and mental health, namely physiological function ( PF ), role physical ( RP ), bodily pain ( BP ), general health ( CH ), vitality ( VT ), social function ( SF ), role emotional ( RE ), mental health ( MH ). In addition, the SF-36 scale also includes another indicator - health change ( HT ), which is used to evaluate health changes over the past year.Add the scores of each item to the actual score, and then calculate the final score RP according to the following formula. The higher the RP score, the better the health status.

    Time frame: Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.

Secondary outcomes

  1. Insomnia Severity Index(ISI)

    The patients were evaluated by ISI scale at each observation point. According to the total score, the degree of insomnia is divided into the following degrees:The total score between 0 and 7 indicates no clinically significant insomnia, the total score between 8 and 14 indicates subthreshold insomnia, the total score between 15 and 21 indicates clinical insomnia ( moderate to severe ), and the total score between 22 and 28 indicates clinical insomnia ( severe ).

    Time frame: Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.

  2. Dysfunctional Beliefs and Attitudes about Sleep Scale 16,DBAS-16 (DBAS-16)

    There were 16 items in DBAS-16, including 4 factors : an estimated factor for the consequences of insomnia ; worry about sleep factor ; expectation factors of sleep ; cognition factors of insomnia drugs.The lower the total score, the more likely it is that the subjects ' cognition of sleep is biased.

    Time frame: Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.

  3. GABA

    GABA is the most important inhibitory neurotransmitter in the central nervous system. In clinical studies, proton magnetic resonance spectroscopy showed that GABA in the brain of patients with primary insomnia was 30 % lower than that of normal people, and sleep time was prolonged with the increase of GABA content.

    Time frame: Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.

  4. Glx

    Glutamate glutamine complex ( Glx ) is glutamic acid ( Glu ) + glutamine ( Gln ). Glu is the main excitatory neurotransmitter, maintaining the excitability of organisms. In the clinical study, the content of Glu in the brain of insomnia patients was analyzed by EEG ultra-slow fluctuation technique. The results showed that the content of Glu in insomnia patients increased.

    Time frame: Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.

07

Study locations

1 of 1 sites recruiting
  • The Third Affiliated Hospital of Zhejiang Chinese Medical University
    Hangzhou, Zhejiang 321000, China
    Recruiting
08

References and documents

Publications

  • Fu S, He K, Zhou C. Curative Effect and Autonomic Nerve Function of Patients With Primary Insomnia of Liver Depression and Spleen Deficiency Type Based on the Acupoint Selection of Meridian Theory: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2026 Jan 22;15:e84122. doi: 10.2196/84122. PubMed 41570299 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06782815
Lead sponsor
Chuanlong Zhou
Responsible party
Chuanlong Zhou (Deputy Chief Chinese Physician, The Third Affiliated hospital of Zhejiang Chinese Medical University) — Sponsor-investigator
First posted
Jan 20, 2025
Start date
Jan 1, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 11, 2025

Study contacts

Zhou CL Zhou Chuanlong
Contact
471388079@qq.com
15868486255

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion